Research programme: Epidermal growth factor receptor targeted therapeutics - SpringWorks Therapeutics
Latest Information Update: 07 Nov 2022
At a glance
- Originator Dana-Farber Cancer Institute; Stanford University School of Medicine
- Developer Dana-Farber Cancer Institute; SpringWorks Therapeutics; Stanford University School of Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lung cancer
Most Recent Events
- 07 Nov 2022 Preclinical trials in Lung cancer (Combination therapy) in USA (unspecified route) (SpringWorks Therapeutics pipeline, November 2022)
- 07 Nov 2022 Preclinical trials in Lung cancer (Monotherapy) in USA (unspecified route) (SpringWorks Therapeutics pipeline, November 2022)
- 20 Oct 2021 SpringWorks therapeutics and Ab Magnitude enters in to R&D agreement for epidermal growth factor receptor targeted therapeutics